|
|
 |
|
|
|
|
|
|
Investigational compounds.
Bristol-Myers Squibb has nearly 40 compounds in development, six in full development. Bristol-Myers Squibb researchers are dedicated to discovering and developing innovative, cost-effective medicines that address unmet medical needs. These areas, listed below, were selected with an emphasis on where the future of medicine and patient needs match our internal strengths.
Alzheimer's/Dementia
Atherosclerosis/Thrombosis
Cancer
Diabetes
Hepatitis
HIV
Obesity
Rheumatoid Arthritis & Related Diseases
Solid Organ Transplant Rejection
Last updated April, 2008
|
|
|
|
[Top Page] [Search]
[Index] [Contact] [Home]
Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.
© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy. |
|
|
